To assess the number of individuals visually impaired or blind due to glaucoma and to examine regional differences and temporal changes in this parameter for the period from 1990 to 2012.
As part of the Global Burden of Diseases (GBD) Study 2010, we performed a systematic literature review for the period from 1980 to 2012. We primarily identified 14,908 relevant manuscripts, out of which 243 high-quality, population-based studies remained after review by an expert panel that involved application of selection criteria that dwelt on population representativeness and clarity of visual acuity methods used. Sixty-six specified the proportion attributable to glaucoma. The software tool DisMod-MR (Disease Modeling–Metaregression) of the GBD was used to calculate fraction of vision impairment due to glaucoma.
In 2010, 2.1 million (95% Uncertainty Interval (UI):1.9,2.6) people were blind, and 4.2 (95% UI:3.7,5.8) million were visually impaired due to glaucoma. Glaucoma caused worldwide 6.6% (95% UI:5.9,7.9) of all blindness in 2010 and 2.2% (95% UI:2.0,2.8) of all moderate and severe visual impairment (MSVI). These figures were lower in regions with younger populations (<5% in South Asia) than in high-income regions with relatively old populations (>10%). From 1990 to 2010, the number of blind or visually impaired due to glaucoma increased by 0.8 million (95%UI:0.7, 1.1) or 62% and by 2.3 million (95%UI:2.1,3.5) or 83%, respectively. Percentage of global blindness caused by glaucoma increased between 1990 and 2010 from 4.4% (4.0,5.1) to 6.6%. Age-standardized prevalence of glaucoma related blindness and MSVI did not differ markedly between world regions nor between women.
Citation: Bourne RRA, Taylor HR, Flaxman SR, Keeffe J, Leasher J, Naidoo K, et al. (2016) Number of People Blind or Visually Impaired by Glaucoma Worldwide and in World Regions 1990 – 2010: A Meta-Analysis. PLoS ONE 11(10): e0162229. https://doi.org/10.1371/journal.pone.0162229
Editor: Yuk Fai Leung, Purdue University, UNITED STATES
Received: April 8, 2016; Accepted: August 20, 2016; Published: October 20, 2016
Copyright: © 2016 Bourne et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Data Availability: Table B in S3 Appendix of the Supplementary Material gives a reference for each of the data sources available in the published literature. Data sources that cannot be found publicly are also listed with information on whether microdata was supplied, whether the study involved rapid assessment methodology and other notes that may assist the reader. Other data are available from the Global Vision Database (http://www.globalvisiondata.org/). Some principal investigators of studies that are included in this database supplied detailed data on condition that only summary data would be publicly accessible hence the restriction on complete access to the completely disaggregated dataset. These data are owned by the principal investigators and cannot be made publicly available without permission of the Global Vision Database Data Access Committee. The Global Vision Database data files are stored securely at Anglia Ruskin University, Cambridge, UK, according to the university's information security guidelines. Qualified researchers who wish to request access to the third party data may contact the Global Vision Database through the website (http://www.globalvisiondata.org/contact.html) or using the following contact information: Professor Shahina Pardhan. Email: firstname.lastname@example.org. Address: Vision & Eye Research Unit, Postgraduate Medical Institute, Anglia Ruskin University, East Road, Cambridge, UK.
Funding: This study was partially funded by the Bill & Melinda Gates Foundation, Fight for Sight, Fred Hollows Foundation and the Brien Holden Vision Institute. The results in this paper are prepared independently of the final estimates of the Global Burden of Diseases, Injuries, and Risk Factors study. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing interests: The authors have declared that no competing interests exist.
Previous population-based investigations have shown that glaucoma is one of the most common, and thus most important, causes for vision loss worldwide [1–34]. Previous estimations of global burden of glaucoma were based on meta-analyses which did not include studies, as far as available, from all regions of the world, which did not include all available population-based studies, which did not assess a change during the last 2 decades, or which mostly reported on the prevalence of the disease [1–3]. Many of the population-based glaucoma studies did not report on the number of people blind or visually impaired due glaucoma. For public health purposes, however, the number of patients functionally affected is more important than the number of patients with any stage of the disease. For the individual patient and thus for the society, the burden of a disease is more important than just the presence of a disease including its early stages. We therefore conducted this meta-analysis of all available population-based studies performed worldwide within the last two decades to estimate the number of people affected by blindness (defined as presenting visual acuity <3/60) and moderately to severe visual impairment (MSVI; presenting visual acuity <6/18, ≥3/60) due to glaucoma, to assess changes in that figures during the period from 1990 to 2010, to examine regional differences in the prevalence of glaucoma related blindness and MSVI, and finally to compare the number of blind and visually impaired people with glaucoma with the number of people blind and visually impaired due to other diseases.
In a systemic literature research we used the systems of Medline, Embase and the WHO (World Health Organization) library information system to search for articles on vision loss and published in the period between 1980 and 2012. The methodology for this systematic review is described in Fig 1 as a PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) flowchart with a PRISMA checklist in S1 Appendix. The search strategy is presented in S2 Appendix. Out of primarily identified 14,908 relevant manuscripts, we selected 243 high-quality, population-based studies after review by an expert panel. The latter involved application of selection criteria that were based on population representativeness and clarity of visual acuity methods used. As described in detail recently, search terms included concepts to describe “blindness”, “visual impairment”, “population”, “eye”, “survey”, and a list of ocular disorders [35–37]. Additional unpublished data sources were found by personal communication with researchers identified in the literature search. Population-based studies that reported prevalence of visual impairment and blindness disaggregated by cause (128 studies) provided the basic data to calculate the proportion of blindness and MSVI that were due to glaucoma, besides other causes such as cataract, macular degeneration, diabetic retinopathy, trachoma, or undercorrection of refractive error. A full list of data sources used for each cause has been presented recently (Table B in S3 Appendix) . Two studies per region were available for 18 of the 21 GBD (Global Burden of Disease) Study regions, while only one study was identified for Central Europe. Eastern Europe and Central Africa did not have any study with cause-specific data. No study was identified for 126 of 191 countries. Data were extracted from published and unpublished reports into an electronic database (Microsoft Excel) by two investigators working independently with consistency checks in order to minimize data inputting errors. Extracted data included prevalence of predefined severities of vision loss by age, gender, country, region, and cause.
Stratifying by age, sex, and geographical region, we estimated trends in causes of vision impairment and included an analysis of uncertainties. For geographical stratification, we used the 21 regions defined in the GBD Study . As part of the statistical analysis, we first identified and accessed the data and then estimated fractions for each cause. We stratified the results by the severity of vision impairment, sex, age, and region. We finally applied the cause fractions to the prevalence of all-cause presenting vision impairment . The method has been described in detail previously .
For the statistical analysis, the Disease Modeling–Metaregression (DisMod-MR) model from the GBD Study was used to determine the fraction of vision impairment caused by glaucoma or due to other causes mentioned above (more detailed information is available in S3 Appendix with an explanation of country and regional groupings, Table A, and a full list of citations of the studies, Table B) . Briefly, the DisMod-MR model is a negative binomial regression model which included the following elements: covariates that predicted the variation in the true proportion of vision impairment from each disease; fixed effects that adjusted for definitional differences (e.g. whether the causes of presenting vs. best-corrected vision impairment were reported); a hierarchical model structure which fitted random intercepts in individual countries derived from the data observed in the country, in its region, and in other regions based on the availability and consistency of country- and region-specific data; age-specific fixed-effects which allowed for a non-linear age pattern; and a fixed effect for data on males. For the assessment of the fractions of blindness and visual impairment which were caused by glaucoma, we fitted one DisMod-MR model and used three covariates: an indicator variable which described whether the data were for blindness or for MSVI, an indicator variable describing whether the data were based on presenting visual acuity or best-corrected visual acuity measurements, and a country-level covariate which reflected the health systems access. We made two sets of the prediction for glaucoma, one for best-corrected blindness and one for best-corrected MSVI. Using the WHO reference population, we age-standardized the prevalences . We also calculated the numbers of people with vision impairment and blindness caused by glaucoma. It reflected each region’s population size and age structure.
Blindness caused by glaucoma was found to be present in 2.1 million (95% uncertainty interval (UI): 1.9, 2.6) people, and MSVI caused by glaucoma was detected for 4.2 million (95%UI: 3.7–5.8) million individuals (Table 1). Taking into account that overall 32.4 million people were blind and 191 million people were vision impaired in 2010, glaucoma caused worldwide 6.6% (95%UI: 5.9, 7.9) of all causes for blindness in 2010 and 2.2% (95%UI: 2.0, 2.8) of all causes for MSVI (Table 1) . The percentage of blindness caused by glaucoma varied from <5% in South Asia, East and West Sub-Saharan Africa, and Oceania, to 15.5% (9.5–21.9%) in Tropical Latin America.
From the baseline in 1990 to 2010 the number of individuals blind due to glaucoma increased by 0.8 million (95%UI: 0.7, 1.1) and the number of individuals with MSVI due to glaucoma increased by 2.3 million (95%UI: 2.1, 3.5) (Tables 1 and 2). If only individuals with an age of 50+ years were included, the number of people blind due to glaucoma increased from 1.3 million (95%UI: 1.2, 1.6) in 1990 to 2.0 million (95%UI: 1.8, 2.5) in 2010, and the number of individuals with glaucoma related visual impairment increased from 1.9 million (95%UI: 1.5, 2.3) in 1990 to 3.8 million (95%UI: 3.3, 5.3) in 2010. Compared with 1990, the percentage of global blindness caused by glaucoma increased from 4.4% (4.0, 5.1) to 6.6% (Tables 1 and 2). World regions with older populations such as the high-income regions, Southern Latin America, and Central and Eastern Europe, as compared to regions with younger populations showed a higher percentage of blindness caused by glaucoma in 1990 and in 2010 (Table 1). The increase in the percentage of global blindness caused by glaucoma from 1990 to 2010 had taken place in all world regions without major difference between them (Tables 1 and 2).
Age-standardized prevalence of glaucoma related blindness was worldwide 0.1% (95%UI: 0.1, 02) in adults aged 50+ years in 2010, and the age-standardized prevalence of MSVI caused by glaucoma was worldwide 0.3% (95%UI: 0.2, 0.4) (Table 1). Compared with 1990, the age-standardized prevalence of glaucoma-related blindness was reduced from 0.2% (95%UI: 0.1, 0.2) to 0.1% and the prevalence of glaucoma-related MSVI increased from 0.2% (95%UI: 0.2, 0.3) to 0.3% (Tables 1 and 2).
With respect to sex, the age-standardized prevalence of glaucoma related blindness among women (0.1%; 95%UI: 0.1, 0.2) and men (0.1%; 95%UI: 0.1, 0.2) did not differ. The same held true for the age-standardized prevalence of MSVI due to glaucoma (0.3% (95%UI: 0.2, 0.4) in women versus 0.3% (95%UI: 0.3, 0.4) in men).
Glaucoma was the cause for blindness in 2.1 million people or 6.6% of overall 32.4 million blind people globally in 2010, and glaucoma was the cause for MSVI in 4.2 million people or 2.2% of overall 191 million people visually impaired in 2010 . These figures are lower than those reported by Quigley and Broman who forecasted in 2005 that in 2010, bilateral glaucoma related blindness would affect 8.4 million people . Quigley and Broman discussed the difference between their estimate and an estimate of 4.4 million that was the most recent estimate at the time by the WHO Vision Group published by Resnikoff et al. . Quigley and Broman argued that the difference was due to methodological issues given that blindness prevalence surveys often assigned the most ‘‘treatable” disease as the primary cause of blindness. It is often assumed that cataract is more treatable than glaucoma, which leads to an underestimation of glaucoma blindness. In the recent analysis of global blindness, glaucoma ranked third together with macular degeneration (both: 6.6% of all blind people globally) after cataract (33.4% of all blind people globally) and undercorrection of refractive error (20.9%) in the list of the most common causes of global blindness . Glaucoma and macular degeneration ranked first in the list of most common irreversible causes of blindness. With respect to MSVI, glaucoma ranked fourth (2.2%) after undercorrection of refractive error (52.9% of all people with MSVI globally), cataract (18.4%) and macular degeneration (2.2%) in the list of the most common causes of MSVI worldwide. These data confirm previous studies and meta-analyses which showed that glaucoma had a prominent ranking in the frequency list of causes for blindness and visual impairment. In contrast to the previous landmark study by Quigley and Broman, glaucoma was ranked third and fourth in our study as compared to being ranked second by Quigley and Broman and more recently Pascolini et al. as cause for blindness worldwide [2,41]. The numbers however also show that on a global perspective, cataract and undercorrection of refractive error are by far more prevalent as causes for blindness and MSVI. Only one out of 15 blind people was blind due to glaucoma, and only one out of 45 visually impaired people was visually impaired due to glaucoma. These figures may suggest that from a public health of view, providing adequate glasses for correction of refractive error and supplying cataract surgery to the blind and visually impaired may be at least as important as glaucoma care. In the recent meta-analysis of population-based studies by Tham and colleagues, the global prevalence of glaucoma in the population aged 40 to 80 years was 3.54% (95% Credible Intervals, 2.09, 5.82), and the number of individuals aged 40 to 80 years and affected by glaucoma worldwide was 64.3 million in the year 2013 . These figures cannot directly be compared with the figures found in our investigation since Tham´s study addressed the number of individuals affected by glaucoma, independently of the stage of the disease, while our study assessed the number of individuals visually impaired or blind due to glaucoma.
The percentage of blindness caused by glaucoma showed regional variations, with relatively low figures in regions with relatively young populations such as South Asia and Sub-Saharan Africa, and with relatively high figures in regions with relatively old populations such as the high-income regions (Tables 1 and 2). It was due to the dependence of the prevalence of glaucoma on age, while other causes for blindness and MSVI, namely undercorrection of refractive error and, to a lesser degree, cataract occurred also in younger groups of the population. These regional differences in the percentage of glaucoma as cause for blindness and MSVI remained mostly unchanged in the period from 1990 to 2010, since the differences in the age structure between the various world regions did not markedly change.
The global number of glaucoma blind increased by 0.8 million in the period from 1990 to 2010, although the age-standardized global prevalence of glaucoma related blindness in adults aged 50+ years decreased from 0.2% to 0.1%. The worldwide demographic transition with increasing population size, substantial increase in the average age in most regions and falling death rates more than outweighed the decrease in the prevalence of glaucoma related blindness so that the absolute numbers increased by 0.8 million or 62% from 1990 to 2010. The global prevalence of glaucoma related MSVI increased from 0.2% to 0.3% from 1990 to 2010, leading to marked increase in the absolute number of people visually impaired by glaucoma by 2.3 million or 83% in the same period. These figures show that, despite the relatively low percentage of glaucoma related blindness and MSVI on all causes of blindness and MSVI, an intensification of measures to address the growing number of people blind or visually impaired by glaucoma appears mandatory.
Expressed in percentage points, the age-standardized global prevalence of cataract, undercorrected refractive error and trachoma showed marked declines between 1990 and 2010 as reported previously . The age-standardized prevalence of glaucoma declined less (for blindness) or even increased slightly (for MSVI). Similar findings were observed for the age-standardized prevalence of macular degeneration and diabetic retinopathy . These developments may indicate a shift in the relative importance of the various diseases as causes for blindness and visual impairment, with a decrease for the major causes of cataract and undercorrection refractive error, which are relatively easily, safely and cost efficiently treatable, unlike diseases such as glaucoma, macular degeneration and diabetic retinopathy for which the therapy takes considerably more time and effort with a markedly lower rate of success.
Globally and in all regions, a larger percentage of blindness and MSVI caused by cataract and macular degeneration occurs in women than in men . Globally, 36% of blindness among women was caused by cataract versus 30% of blindness among men; for MSVI, the figures were 20% versus 16%, respectively. In a similar manner, macular degeneration caused 7.3% of blindness among women versus 5.5% of blindness among men . The glaucoma related blindness and MSVI did not show such marked disparities by sex in our study. This differs from the predictions of Quigley and Broman who estimated that 59% of all people with glaucoma of any stage would be women in 2010.
Literature reviews published by the WHO and the WHO Prevention of Blindness and Deafness program have previously been used to make worldwide estimates of numbers of people blind or with vision impairment. The latest of these studies included literature published in the period from 2000 to 2010 . That analysis was limited to three age groups, with no breakdown by sex, provision of a point estimate for 2010, or estimates for the six WHO epidemiological subregions within a more limited timeframe. Interestingly, the figures for the percentage of blindness and MSVI caused by glaucoma did not markedly differ between Pascolini and Mariotti´s study and our study (glaucoma related blindness: 2% versus 2.2%; glaucoma related MSVI: 8% versus 6.0%) .
The present study forms part of a series of investigations on the prevalence and causes of vision loss in different world regions and on the number of individuals affected by MSVI and blindness caused by the major disorders of under-correction of refractive error, cataract, macular degeneration, diabetic retinopathy and glaucomatous optic neuropathy [42–51]. Applying the same statistical method (DisMod-MR) as the previous investigation, the present study addressed the number of individuals affected by glaucoma as cause for their MSVI or blindness. These figures may be of interest and help for politicians to direct financial means for the improvement of public health with respect to MSVI and blindness and to direct financial support for research in specific fields of medicine and in particular of ophthalmology. The previous studies of the series either assessed the worldwide prevalence of MSVI and blindness or examined the number of people affected by the main ocular disorders except for glaucomatous optic neuropathy.
The figure of 2.1 million individuals blind due to glaucoma and of 4.2 million individuals visually impaired due to glaucoma (representing 6.6% of all blindness and 2.2% of all MSVI worldwide) were lower than the figures of 10.8 million people blind and 35.1 million visually impaired due to cataract (representing 33.4% of all blindness and 18.4% of all MSVI worldwide), and also lower than the figures of 6.8 million people blind and 101.2 million people vision impaired due to undercorrected refractive errors (representing 20.9% of all blindness and 52.9% of all MSVI worldwide) [49,51]. The figures of glaucoma associated blindness and MSVI were similar to the numbers of 2.1 million individuals blind and 6.0 million individuals visually impaired due to macular diseases (representing 6.6% of all blindness and 3.1% of all vision impairment) . They were higher than the figures of 0.8 million people were blind due to diabetic retinopathy and 3.7 million visually impaired due to diabetic retinopathy (2.6% of all blindness and 1.9% of all MSVI worldwide) .
The design of our study had potential limitations. First, as we discussed in our report of global prevalence of vision loss, a significant limitation was that many country-years lacked data, or there was only sub-national data available . Relatively few national studies reported vision impairment for all ages and for all causes. Second, some data sources did not present the prevalence by age. By imputing age-specific cause fractions we were able to utilize this data with the assumption that the age pattern of the vision impaired in the particular study matched the modeled age pattern in the country where the study was conducted . Third, the majority of population-based studies within the database that reported on vision loss due to glaucoma did not disaggregate their reported findings into glaucoma diagnostic subtypes such as open-angle glaucoma and angle-closure glaucoma, therefore it was not possible to differentiate between glaucoma subtypes in our analysis. Fourth, protocol dictated that population-based studies will report one cause as the principal cause for an individual examined in that individual study, so that causal prevalence can be calculated. In situations where multiple disorders contribute equally to visual loss, only the ‘‘most easily preventable” or the ‘‘most readily curable” cause is usually recorded . This approach can underestimate the impact of diseases such as diabetic retinopathy and glaucoma when a study participant presents with cataract, while underestimating cataract burden when study participants also have an uncorrected refractive error . Finally, the relatively small sample size of some studies meant that the confidence intervals of cause-specific prevalence estimates were relatively large. Our methods did however take sample size into account, so small sample size studies had less influence on the estimates than larger studies. Strengths of this study included the large amount of population-based data accessed and utilized and the trend analysis of causes of vision impairment and blindness, usage of non-linear age trends and modeling of data that were not reported by age, systematic quantitative analysis and reporting of uncertainty intervals. The large size of network of ophthalmologic researchers involved in first identification and then evaluation of data sources allowed access to unpublished materials and permitted us to obtain additional unpublished data from study investigators who had only published summary data, to evaluate all the major vision impairment studies, and to include only studies that met specific inclusion criteria regarding population representativeness and clear description and definition of visual acuity procedures.
In conclusion, in 2010, 2.1 million people were blind and 4.2 million people were visually impaired due to glaucoma. The number of people blind and visually impaired due to glaucoma increased by 0.8 million people or 62% and by 2.3 million people or 83%, respectively, in the period from 1990 to 2010. The contribution of glaucoma to total blindness and MSVI was higher in high-income regions with relatively older populations. One out of 15 blind people was blind due to glaucoma, and one out of 45 visually impaired people was visually impaired due to glaucoma.
S1 Appendix. PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) checklist.
S2 Appendix. The Search Strategy for the Systematic Review.
Benita J O’Colmain (ICF International Inc, 530 Gaither Road, Suite 500, Rockville, MD 20850, USA) assisted with the incorporation of microdata from several large population-based studies. The principal investigators of these and other studies are thanked for authorizing unpublished study data to be used in this project. Colin Mathers (World Health Organization, Geneva, Switzerland) greatly assisted in the communications between the GBD Core Group and the GBD Vision Loss Expert Group. Holly Price assisted in the preparation of data for the analysis.
The following authors are members of the Vision Loss Expert Group of the Global Burden of Disease Study [the lead author for this group is Rupert Bourne; Email address: email@example.com]
Rupert R A Bourne (Anglia Ruskin University, Cambridge, UK); Peter Ackland (International Agency for Prevention of Blindness, London, UK); Aries Arditi (Visibility Metrics LLC, New York, USA); Yaniv Barkana (Assaf Harofe Medical Center, Zerifin, Israel); Banu Bozkurt (Department of Ophthalmology, Meram Medical Faculty, Selcuk University, Konya, Turkey); Tasanee Braithwaite (Moorfields Eye Hospital, London, UK); Alain Bron (Service d’Ophtalmologie CHU Dijon, France); Donald Budenz (University of Miami, Miami, USA); Feng Cai (Green-Valley Group, Freedom, California, USA); Robert Casson (University of Adelaide, Australia); Usha Chakravarthy (The Queen’s University of Belfast, Belfast, Northern Ireland); Jaewan Choi (Hangil Eye Hospital, Incheon, South Korea); Maria Vittoria Cicinelli (San Raffaele Scientific Institute, Milan, Italy); Nathan Congdon (The Queen’s University of Belfast, Belfast, Northern Ireland); Reza Dana (Massachusseets Eye & Ear Infirmary, Harvard Medical School, Boston, USA); Rakhi Dandona (George Institute for International Health, Sydney, Australia); Lalit Dandona (Public Health Foundation of India, New Delhi, India); Aditi Das (St James’s University Hospital, Leeds, UK); Iva Dekaris (Eye Clinic Svjetlost, Zagreb, Croatia); Monte Del Monte (University of Michigan, Ann Arbor, USA); Jenny Deva (Universiti Tunku Abdul Rahman, Dept of Surgery (Ophthalmology), Cheras, Malaysia); Laura Dreer (University of Alabama, Birmingham, USA); Leon Ellwein (National Eye Institute, Bethesda, USA); Marcela Frazier (University of Alabama, Birmingham, USA); Kevin Frick (Johns Hopkins Bloomberg School of Public Health, Baltimore, USA); David Friedman (Johns Hopkins Bloomberg School of Public Health, Baltimore, USA); Joao Furtado (University of Sao Paulo, Sao Paulo Brazil); Hua Gao (Henry Ford Medical Center, Dept of Ophthalmology, Michigan, USA); Andrew Gazzard (Institute of Ophthalmology, London, UK); Ronnie George (Medical Research Foundation, Chennai, India); Stephen Gichuhi (University of Nairobi, Nairobi, Kenya); Victor Gonzalez (Valley Retina Institute, Texas, USA); Billy Hammond (University of Georgia, Athens, USA); Mary Elizabeth Hartnett (University of Utah, Salt Lake City, USA); Minguang He (University of Melbourne, Melbourne, USA); James Hejtmancik (National Eye Institute, Bethesda, USA); Flavio Hirai (Federal University of Sao Paulo, Brazil); John Huang (Yale University School of Medicine, Connecticut, USA); April Ingram (Alberta Children’s Hospital, Calgary, Canada); Jonathan Javitt (Johns Hopkins University School of Medicine, Baltimore, USA); Jost Jonas (Department of Ophthalmology, Medical Faculty of Mannheim, Heidelberg, Germany); Charlotte Joslin (University of Illinois, Chicago, USA); Jill Keeffe (L V Prasad Eye Institute, Hyderabad, India); John Kempen (University of Pennsylvania Perelman School of Medicine, Philadelphia, USA); Moncef Khairallah (University Hospital Monastir, Tunisia); Rohit Khanna (LV Prasad Eye Institute, Hyderabad, India); Judy Kim (Medical College of Wisconsin, Milwaukee, USA); George Lambrou (Novartis, Basel, Switzerland); Van Charles Lansingh (HelpMeSee, Inc, New York, USA); Paolo Lanzetta (Department of Ophthalmology, University of Udine. Udine, Italy); Janet Leasher (Nova Southeastern University, Florida, USA); Jennifer Lim (University of Illinois, Urbana, USA); Hans Limburg (Health Information Services, Netherlands); Kaweh Mansouri (Clinique De Montchoisi, Lausanne, Switzerland); Anu Mathew (Royal Children’s Hospital, Melbourne, Australia); Alan Morse (Jewish Guild Healthcare, New York, USA); Beatriz Munoz (Wilmer Eye Institute John Hopkins University, Baltimore, USA); David Musch (University of Michigan, Ann Arbor, USA); Kovin Naidoo (University of KwaZulu-Natal, Durban, South Africa); Vinay Nangia (Suraj Eye Institute, Nagpur, India); Maria Palaiou (Massachusetts Eye and Ear Institute, Boston, USA); Maurizio Battaglia Parodi (University Vita Salute, Ospedale San Raffaele, Milan, Italy); Fernando Yaacov Pena (Fundacion Vision, Asuncion, Paraguay); Konrad Pesudovs (NHMRC Centre for Clinical Eye Research, Flinders University, Adelaide, Australia); Tunde Peto (The Queen’s University of Belfast, Belfast, Northern Ireland); Harry Quigley (Wilmer Eye Institute Johns Hopkins University, Baltimore, USA); Murugesan Raju (University of Missouri, Columbia, USA); Pradeep Ramulu (Wilmer Eye Institute Johns Hopkins University, Baltimore, USA); Serge Resnikoff (Brien Holden Vision Institute, Sydney, Australia); Dana Reza (Schepens Eye Research Institute/Mass Eye and Ear, Harvard Medical School, Boston, USA); Alan Robin (Johns Hopkins University, Baltimore, USA); Luca Rossetti (University of Milan, Milan, Italy); Jinan Saaddine (National Center for Chronic Disease Prevention and Health Promotion, Atlanta, USA); Mya Sandar (Singapore Eye Research Institute, Singapore); Janet Serle (Mt Sinai School of Medicine, New York, USA); Tueng Shen (University of Washington, Seattle, USA); Rajesh Shetty (Mayo Clinic, Minnesota, USA); Pamela Sieving (National Institutes of Health, Bethesda, USA); Juan Carlos Silva (Pan-American Health Organisation, Columbia); Alex Silvester (St Paul’s Eye Unit, Royal Liverpool University Hospital, Liverpool, UK); Rita Sitorus (Department of Ophthalmology, Faculty of Medicine, University of Indonesia, Depok, Indonesia); Dwight Stambolian (University of Pennsylvania, Philadelphia, USA); Gretchen Stevens (World Health Organization, Geneva, Switzerland); Hugh Taylor (Centre for Eye Research Australia, University of Melbourne, Melbourne, Australia); Jaime Tejedor (Hospital Raman y Cajal, Madrid, Spain); James Tielsch (Johns Hopkins Bloomberg School of Public Health, Baltimore, USA); Miltiadis Tsilimbaris (University of Crete Medical School, Crete, Greece); Jan Van Meurs (The Rotterdam Eye Hospital and Erasmus University, Rotterdam, Netherlands); Rohit Varma (Department of Ophthalmology for Keck School of Medicine, University of Southern California, USA); Gianni Virgili (Department of Ophthalmology, University of Florence, Italy); Jimmy Volmink (Faculty of Health Sciences, Stellenbosch University, South Africa); Ya Xing Wang (Capital Medical University, Beijing, China); Ning-Li Wang (Eye Centre of Beijing Tongren Hospital, Beijing, China); Sheila West (Johns Hopkins Hospital, Baltimore, USA); Peter Wiedemann (Leipzig University, Leipzig, Germany); Tien Wong (University of Melbourne, Melbourne, Australia); Richard Wormald (Moorfields Eye Hospital, London, UK); Yingfeng Zheng (Singapore Eye Research Institute, Singapore)
- Conceived and designed the experiments: RRAB SRF RAW.
- Analyzed the data: SRF RAW.
- Wrote the paper: RRAB HRT JK JL KN KP TYW SR JBJ.
- 1. Quigley HA. Number of people with glaucoma worldwide. Br J Ophthalmol. 1996;80: 389–393. pmid:8695555
- 2. Quigley HA, Broman AT. The number of people with glaucoma worldwide in 2010 and 2020. Br J Ophthalmol. 2006;90: 262–267. pmid:16488940
- 3. Tham YC, Li X, Wong TY, Quigley HA, Aung T, Cheng CY. Global prevalence of glaucoma and projections of glaucoma burden through 2040: a systematic review and meta-analysis. Ophthalmology 2014;121: 2081–2090. pmid:24974815
- 4. Shiose Y, Kitazawa Y, Tsukahara S, Akamatsu T, Mizokami K, Futa R, et al. Epidemiology of glaucoma in Japan—a nationwide glaucoma survey. Jpn J Ophthalmol. 1991;35: 133–155. pmid:1779484
- 5. Tielsch JM, Katz J, Singh K, Quigley HA, Gottsch JD, Javitt J, et al. A population-based evaluation of glaucoma screening: the Baltimore Eye Survey. Am J Epidemiol. 1991;134: 1102–1110. pmid:1746520
- 6. Congdon N, Wang F, Tielsch JM. Issues in the epidemiology and population based screening of primary angle-closure glaucoma. Surv Ophthalmol. 1992;36: 411–423. pmid:1589856
- 7. Klein BE, Klein R, Sponsel WE, Franke T, Cantor LB, Martone J, et al. Prevalence of glaucoma. The Beaver Dam Eye Study. Ophthalmology. 1992;99: 1499–1504. pmid:1454314
- 8. Salmon JF, Mermoud A, Ivey A, Swanevelder SA, Hoffman M. The prevalence of primary angle-closure glaucoma and open angle glaucoma in Mamre, Western Cape, South Africa. Arch Ophthalmol. 1993;111:1263–1269. pmid:8363470
- 9. Dielemans I, Vingerling JR, Wolfs RC, Hofman A, Grobbee DE, de Jong PT. The prevalence of primary open-angle glaucoma in a population-based study in The Netherlands. The Rotterdam Study. Ophthalmology. 1994;101: 1851–1855. pmid:7800368
- 10. Leske MC, Connell AM, Schachat AP, Hyman L. The Barbados Eye Study. Prevalence of open angle glaucoma. Arch Ophthalmol. 1994;112: 821–829. pmid:8002842
- 11. Foster PJ, Baasanhu J, Alsbirk PH, Munkhbayar D, Uranchimeg D, Johnson GJ. Glaucoma in Mongolia. A population-based survey in Hövsgöl province, northern Mongolia. Arch Ophthalmol 1996;114(10):1235–1241. pmid:8859083
- 12. Mitchell P, Smith W, Attebo K, Healey PR. Prevalence of open-angle glaucoma in Australia. The Blue Mountains Eye Study. Ophthalmology. 1996;103: 1661–1669. pmid:8874440
- 13. Ekström C. Prevalence of open-angle glaucoma in central Sweden. Acta Ophthalmol Scand. 1996;74: 107–112. pmid:8739672
- 14. Wensor MD, McCarty CA, Stanislavsky YL, Livingston PM, Taylor HR. The prevalence of glaucoma in the Melbourne Visual Impairment Project. Ophthalmology. 1998;105: 733–739. pmid:9544649
- 15. Jacob A, Thomas R, Koshi SP, Braganza A, Muliyil J. Prevalence of primary glaucoma in an urban south Indian population. Indian J Ophthalmol. 1998;46:81–86. pmid:9847479
- 16. Dandona L, Dandona R, Mandal P, Srinivas M, John RK, McCarty CA, et al. Angle-closure glaucoma in an urban population in southern India. The Andhra Pradesh eye disease study. Ophthalmology. 2000;107: 1710–1716. pmid:10964834
- 17. Dandona L, Dandona R, Srinivas M, Mandal P, John RK, McCarty CA, et al. Open-angle glaucoma in an urban population in Southern India: the Andhra Pradesh eye disease study. Ophthalmology. 2000;107: 1702–1709. pmid:10964833
- 18. Foster PJ, Oen FT, Machin D, Ng TP, Devereux JG, Johnson GJ, et al. The prevalence of glaucoma in Chinese residents of Singapore: a cross-sectional population survey of the Tanjong Pagar district. Arch Ophthalmol. 2000;118: 1105–1111. pmid:10922206
- 19. Buhrmann RR, Quigley HA, Barron Y West SK, Oliva MS, Mmbaga BB. Prevalence of Glaucoma in a rural East African population. Invest Ophthalmol Vsi Sci. 2000;41: 40–48.
- 20. Quigley HA, West SK, Rodriguez J, Munoz B, Klein R, Snyder R. The prevalence of glaucoma in a population-based study of Hispanic subjects: Proyecto VER. Arch Ophthalmol. 2001;119: 1819–1826. pmid:11735794
- 21. VanNewkirk MR, Weih L, McCarty CA, Taylor HR. Cause-specific prevalence of bilateral visual impairment in Victoria, Australia: the Visual Impairment Project. Ophthalmology. 2001;108: 960–967. pmid:11320028
- 22. Buch H, Vinding T, Nielsen NV. Prevalence and causes of visual impairment according to World Health Organization and United States criteria in an aged, urban Scandinavian population: the Copenhagen City Eye Study. Ophthalmology. 2001;108: 2347–2357. pmid:11733284
- 23. Rotchford AP, Johnson GJ. Glaucoma in Zulus: a population-based cross-sectional survey in a rural district in South Africa. Arch Ophthalmol. 2002;120: 471–478. pmid:11934321
- 24. Ramakrishnan R, Nirmalan PK, Krishnadas R, Thulasiraj RD, Tielsch JM, Katz J, et al. Glaucoma in a rural population of southern India: the Aravind comprehensive eye survey. Ophthalmology. 2003;110: 1484–1490. pmid:12917161
- 25. Bourne RR, Sukudom P, Foster PJ, Tantisevi V, Jitapunkul S, Lee PS, et al. Prevalence of glaucoma in Thailand: a population-based survey in Rom Klao district, Bangkok. Br J Ophthalmol. 2003;87: 1069–1074. pmid:12928267
- 26. Varma R, Ying-Lai M, Francis BA, Nguyen BB, Deneen J, Wilson MR, et al. Prevalence of open-angle glaucoma and ocular hypertension in Latinos: the Los Angeles Latino Eye Study. Ophthalmology. 2004;111: 1439–1448. pmid:15288969
- 27. Iwase A, Suzuki Y, Araie M, Yamamoto T, Abe H, Shirato S, et al. The prevalence of primary open-angle glaucoma in Japanese: the Tajimi Study. Ophthalmology. 2004;111: 1641–1648. pmid:15350316
- 28. Hsu WM, Cheng CY, Liu JH, Tsai SY, Chou P. Prevalence and causes of visual impairment in an elderly Chinese population in Taiwan: the Shihpai Eye Study. Ophthalmology. 2004;111: 62–69. pmid:14711715
- 29. Yamamoto T, Iwase A, Araie M, Suzuki Y, Abe H, Shirato S, et al. The Tajimi Study report 2: prevalence of primary angle closure and secondary glaucoma in a Japanese population. Ophthalmology. 2005;112: 1661–1669. pmid:16111758
- 30. He M, Foster PJ, Ge J, Huang W, Zheng Y, Friedman DS, et al. Prevalence and clinical characteristics of glaucoma in adult Chinese: a population-based study in Liwan District, Guangzhou. Invest Ophthalmol Vis Sci. 2006;47: 2782–2788. pmid:16799014
- 31. Topouzis F, Wilson MR, Harris A, Anastasopoulos E, Yu F, Mavroudis L, et al. Prevalence of open-angle glaucoma in Greece: the Thessaloniki Eye Study. Am J Ophthalmol. 2007;144: 511–519. pmid:17893012
- 32. Shen SY, Wong TY, Foster PJ, Loo JL, Rosman M, Loon SC, et al. The prevalence and types of glaucoma in Malay people: the Singapore Malay eye study. Invest Ophthalmol Vis Sci. 2008;49: 3846–3851. pmid:18441307
- 33. Casson RJ, Baker M, Edussuriya K, Senaratne T, Selva D, Sennanayake S. Prevalence and determinants of angle closure in central Sri Lanka: the Kandy Eye Study. Ophthalmology. 2009;116: 1444–1449. pmid:19559485
- 34. Wang YX, Xu L, Yang H, Jonas JB. Prevalence of glaucoma in North China. The Beijing Eye Study. Am J Ophthalmol. 2010;150: 917–924. pmid:20970107
- 35. Bourne R, Price H, Taylor H, Leasher J, Keeffe J, Glanville J, et al.; Global Burden of Disease Vision Loss Expert Group. New systematic review methodology for visual impairment and blindness for the 2010 Global Burden of Disease study. Ophthalmic Epidemiol. 2013;20: 33–39. pmid:23350553
- 36. Stevens G, White R, Flaxman SR, Price H, Jonas JB, Keeffe J, et al.; Global Burden of Disease Vision Loss Expert Group. Global prevalence of visual impairment and blindness: magnitude and temporal trends, 1990–2010. Ophthalmology. 2013;120: 2377–2384. pmid:23850093
- 37. Bourne R, Stevens GA, White RA, Smith J, Flaxman SR, Price H, et al.; Global Burden of Disease Vision Loss Expert Group. Causes of vision loss worldwide: 1990–2010: a systematic analysis. Lancet Global Health. 2013;1: 339–349.
- 38. Murray CJ, Vos T, Lozano R, Naghavi M, Flaxman AD, Michaud C, et al. Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2012;380: 2197–2223. pmid:23245608
- 39. Ahmad O, Boschi-Pinto C, Lopez AD, Murray CJL, Lozano R, Inoue M. Age standardization of rates: a new WHO standard. Geneva: World Health Organization, 2001.
- 40. Resnikofff S, Pascolini D, Etya’ale D, Kocur I, Pararajasegaram R, Pokharel GP, et al. Global data on visual impairment in the year 2002. Bull World Health Organ. 2004;82: 844–851. pmid:15640920
- 41. Pascolini D, Mariotti SP. Global estimates of visual impairment: 2010. Br J Ophthalmol. 2012;96: 614–618. pmid:22133988
- 42. Wong TY, Zheng Y, Jonas JB, Flaxman SR, Keeffe J, Leasher J, et al. Vision Loss Expert Group of the Global Burden of Disease Study. Prevalence and causes of vision loss in East Asia: 1990–2010. Br J Ophthalmol. 2014; 98: 599–604. pmid:24390167
- 43. Naidoo K, Gichuhi S, Basáñez MG, Flaxman SR, Jonas JB, Keeffe J, et al.; Vision Loss Expert Group§ of the Global Burden of Disease Study. Prevalence and causes of vision loss in Sub-Saharan Africa: 1990–2010. Br J Ophthalmol. 2014; 98: 612–618.
- 44. Jonas JB, George R, Asokan R, Flaxman SR, Keeffe J, Leasher J, et al.; Vision Loss Expert Group of the Global Burden of Disease Study. Prevalence and causes of vision loss in Central and South Asia: 1990–2010. Br J Ophthalmol. 2014;98: 592–598. pmid:24457361
- 45. Leasher JL, Lansingh V, Flaxman SR, Jonas JB, Keeffe J, Naidoo K, et al.; Vision Loss Expert Group of the Global Burden of Disease Study. Prevalence and causes of vision loss in Latin America and the Caribbean: 1990–2010. Br J Ophthalmol. 2014;98: 619–628. pmid:24518073
- 46. Khairallah M, Kahloun R, Flaxman SR, Jonas JB, Keeffe J, Leasher J, et al.; Vision Loss Expert Group of the Global Burden of Disease Study. Prevalence and causes of vision loss in North Africa and the Middle East: 1990–2010. Br J Ophthalmol. 2014;98: 605–611. pmid:24590555
- 47. Bourne RRA, Jonas JB, Flaxman SR, Keeffe J, Leasher J, Naidoo K, et al.; Vision Loss Expert Group§ of the Global Burden of Disease Study. Prevalence and causes of vision loss in high-income countries and in Eastern and Central Europe: 1990–2010. Br J Ophthalmol. 2014;98: 629–638. pmid:24665132
- 48. Jonas JB, Bourne RR, White RA, Flaxman SR, Keeffe J, Leasher J, et al.; Vision Loss Expert Group of the Global Burden of Disease Study. Visual impairment and blindness due to macular diseases globally: A systematic review and meta-analysis. Am J Ophthalmol. 2014;158: 808–815. pmid:24973605
- 49. Naidoo KS, Leasher JL, Bourne RR, Flaxman SR, Jonas JB, Keeffe J, et al.; Vision Loss Expert Group of the Global Burden of Disease Study. Global visual impairment due to uncorrected refractive error: 1990–2010. Optom Vis Sci. 2016;93: 227–234. pmid:26905537
- 50. Leasher J, Bourne RR, Flaxman SR, Jonas JB, Keeffe J, Naidoo K, et al.; Vision Loss Expert Group of the Global Burden of Disease Study. Global estimates on the number of people blind or visually impaired by diabetic retinopathy: A meta-analysis from 1990–2010. Diab Care. 2016 In print
- 51. Khairallah M, Kahloun R, Bourne R, Limburg H, Flaxman SR, Jonas JB, et al.; Vision Loss Expert Group of the Global Burden of Disease Study. Number of people blind or visually impaired by cataract worldwide and in world regions, 1990 to 2010. Invest Ophthalmol Vis Sci. 2015; 56: 6762–6769. pmid:26567788
- 52. World Health Organization. Coding instructions for the WHO/PBL eye examination record (version III). PBL/88.1. Available: http://www.who.int/ncd/vision2020_actionplan/ documents/pbl_88_1.pdf. Accessed 18 November 2013
- 53. Kempen JH. The need for a revised approach to epidemiological monitoring of the prevalence of visual impairment. Ophthalmic Epidemiol. 2011;18: 99–102. pmid:21609237